Our partners

JIXING is working with best-in-class investor, RTW, and Bio pharmaceutical partners. 

RTW Investments

RTW Investments (RTW) is a global, full life-cycle investment firm and company builder that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics developing them.

RTW founded JIXING in 2019 and has been supporting the company with an excellent incubation team. RTW previously incubated Rocket Pharmaceuticals (NASDAQ: RCKT), which focuses on developing first-in-class gene therapies for rare and devastating, inherited genetic diseases.

For further information please visit rtwfunds.com.


Cytokinetics (Nasdaq: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics scientists have discovered a robust pipeline of small molecule muscle activators and inhibitors; omecamtiv mecarbil, a cardiac myosin activator; reldesemtiv, a fast skeletal muscle troponin activator (FSTA); aficamten (CK-274) and CK-271, cardiac myosin inhibitors; CK-136, a cardiac troponin activator; and CK-601, a next-generation FSTA.

For further information please visit cytokinetics.com

Milestone Pharmaceuticals

Milestone Pharmaceuticals (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States.

For further information please visit milestonepharma.com

Oyster Point Pharma

Oyster Point Pharma (Nasdaq: OYST) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Oyster Point Pharma’s lead clinical program is focused on the development of Tyrvaya (varenicline), previously called OC-01, nasal spray, a highly selective cholinergic agonist, being developed as a preservative-free nasal spray to treat the signs and symptoms of dry eye disease and neurotrophic keratopathy. In October 2021, Oyster Point announced NDA approval of Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

For further information please visit oysterpointrx.com 


LENZ is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Its lead programs, LNZ100 and LNZ101, are aceclidine-based eye drops designed to restore the loss of near vision associated with presbyopia. Presbyopia is estimated to impact almost two billion people globally and more than 120 million people in the United States. LENZ is headquartered in San Diego, California, and is backed by blue-chip venture capital investors for the development and commercialization of LNZ100 and LNZ101.

For more information, visit: https://lenz-tx.com   


Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione is the only independent company offering a complete range of services, from API, formulation development and devices. Hovione is a company with a culture based on innovation, quality and delivery. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

For more information, please visit www.hovione.com.


TMS is a Tokyo, Japan-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address unmet medical needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus.

The lead pipeline compound, TMS-007, is indicated for the treatment of AIS, which demonstrated efficacy and safety in the completed Phase 2a study in Japan. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market.

For more information about TMS, please visit https://www.tms-japan.co.jp/.